Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 8 - Genetic thrombophilias and antiphospholipid antibodies

  • Edited by Ann Harper
  • Book:
    Haemorrhage and Thrombosis for the MRCOG and Beyond
    Published online:
    05 October 2014
    Print publication:
    01 June 2005, pp 111-127

  • Summary

    Venous thromboembolism (VTE) is a common cause of morbidity and mortality and has been implicated in the pathophysiology of a number of obstetric complications. This chapter provides an overview of the more common genetic thrombophilias and the acquired thrombophilia associated with the presence of antiphospholipid antibodies. A limited number of genetic variants are proven to be independent risk factors for VTE. These include mutations in the genes controlling the function of both pro- and anticoagulant factors. The main benefit in screening thrombophilia is to prevent a first VTE in affected relatives rather than secondary prevention of recurrent VTE. Oral contraceptives increase the risk of VTE, particularly in the first year of use. Women with thrombophilic defects are at greater risk. Improved pregnancy outcomes in women with antiphospholipid syndrome can be achieved with the use of aspirin and low-dose heparin.